다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Journal of neural transmission, v.120 no.3, 2013년, pp.487 - 496
Jost, Wolfgang H. (Department of Neurology, Deutsche Klinik fü) , Hefter, Harald (r Diagnostik, Wiesbaden, Germany) , Stenner, Andrea (Department of Neurology, University of Dü) , Reichel, Gerhard (sseldorf, Dü)
AI-Helper
Botulinum neurotoxin is the therapy of choice for all forms of cervical dystonia (CD), but treatment regimens still vary considerably. The interpretation of treatment outcome is mainly based on the clinical experience and on the scientific value of the rating scales applied. The aim of this review i...
Benecke R Jost WH Kanovsky P Ruzicka E Comes G Grafe S A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia Neurology 2005 64 1949 1951 10.1212/01.WNL.0000163767.99354.C3 15955951
Blackie JD Lees AJ Botulinum toxin treatment in spasmodic torticollis J Neurol Neurosurg Psychiatry 1990 53 8 640 643 10.1136/jnnp.53.8.640 2213040
Brans JW Lindeboom R Snoek JW Zwarts MJ van Weerden TW Brunt ER van Hilten JJ van der Kamp W Prins MH Speelman JD Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial Neurology 1996 46 4 1066 1072 10.1212/WNL.46.4.1066 8780093
Brashear A Lew MF Dykstra DD Comella CL Factor SA Rodnitzky RL Trosch R Singer C Brin MF Murray JJ Wallace JD Willmer-Hulme A Koller M Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia Neurology 1999 53 7 1439 1446 10.1212/WNL.53.7.1439 10534248
Brin MF Lew MF Adler CH Comella CL Factor SA Jankovic J O’Brien C Murray JJ Wallace JD Willmer-Hulme A Koller M Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia Neurology 1999 53 7 1431 1438 10.1212/WNL.53.7.1431 10534247
Burke RE Fahn S Marsden CD Bressman SB Moskowitz C Friedman J Validity and reliability of a rating scale for the primary torsion dystonias Neurology 1985 35 1 73 77 10.1212/WNL.35.1.73 3966004
Cano SJ Warner TT Linacre JM Bhatia KP Thompson AJ Fitzpatrick R Hobart JC Capturing the true burden of dystonia on patients: the Cervical Dystonia Impact Profile (CDIP-58) Neurology 2004 63 9 1629 1633 10.1212/01.WNL.0000142962.11881.26 15534247
Cano SJ Hobart JC Fitzpatrick R Bhatia K Thompson AJ Warner TT Patient-based outcomes of cervical dystonia: a review of rating scales Mov Disord 2004 19 9 1054 1059 10.1002/mds.20055 15372595
Cano SJ Hobart JC Edwards M Fitzpatrick R Bhatia K Thompson AJ Warner TT CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia Neurology 2006 67 12 2230 2232 10.1212/01.wnl.0000249310.25427.f2 17190951
Chan J Brin MF Fahn S Idiopathic cervical dystonia—clinical characteristics Mov Disord 1991 6 119 126 10.1002/mds.870060206 2057004
Comella CL Buchman AS Tanner CM Brown-Toms NC Goetz CG Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance Neurology 1992 42 4 878 882 10.1212/WNL.42.4.878 1565246
Comella CL Stebbins GT Goetz CG Chmura TA Bressman SB Lang AE Teaching tape for the motor section of the Toronto Western Spasmodic Torticollis Scale Mov Disord 1997 12 4 570 575 10.1002/mds.870120414 9251076
Comella CL Leurgans S Wuu J Stebbins GT Chmura T Dystonia Study Group Rating scales for dystonia: a multicenter assessment Mov Disord 2003 18 3 303 312 10.1002/mds.10377 12621634
Consky ES Lang AE Jancovic J Hallett M Clinical assessments of patients with cervical dystonia Therapy with botulinum toxin 1994 New York Marcel Dekker 211 237
Consky ES Basinki A Belle L Ranawaya R Lang AE The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): assessment of validity and inter-rater reliability Neurology 1990 40 suppl 1 445
Costa J Espírito-Santo C Borges A Ferreira JJ Coelho M Moore P Sampaio C Botulinum toxin type A therapy for cervical dystonia Cochrane Database Syst Rev 2005 25 1 CD003633
Costa J Borges A Espírito-Santo C Ferreira J Coelho M Moore P Sampaio C Botulinum toxin type A versus botulinum toxin type B for cervical dystonia Cochrane Database Syst Rev 2005 25 1 CD004314
Costa J Espírito-Santo C Borges A Ferreira JJ Coelho M Moore P Sampaio C Botulinum toxin type B for cervical dystonia Cochrane Database Syst Rev 2005 25 1 CD004315
Dubinsky RM Gray CS Vetere-Overfield B Koller WC Electromyographic guidance of botulinum toxin treatment in cervical dystonia Clin Neuropharmacol 1991 14 3 262 267 10.1097/00002826-199106000-00011 2070367
Fahn S Munsat TL Assessment of primary dystonias Quantification of neurologic deficit 1989 London Butterworths 241 270
Gelb DJ Lowenstein DH Aminoff MJ Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis Neurology 1989 39 1 80 84 10.1212/WNL.39.1.80 2642616
Greene P Kang U Fahn S Brin M Moskowitz C Flaster E Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis Neurology 1990 40 8 1213 1218 10.1212/WNL.40.8.1213 2199847
Jankovic J, Tolosa E (2007) Parkinsons’s disease and movement disorders, 5th edn. Lippincott Williams & Wilkins, Philadelphia
Kamm C Benecke R Botulinum toxin therapy for cervical dystonia: review of the clinical evidence and ongoing studies Clin Invest 2011 1 6 891 900 10.4155/cli.11.63
Lew MF Adornato BT Duane DD Dykstra DD Factor SA Massey JM Brin MF Jankovic J Rodnitzky RL Singer C Swenson MR Tarsy D Murray JJ Koller M Wallace JD Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia Neurology 1997 49 3 701 707 10.1212/WNL.49.3.701 9305326
Lindeboom R Brans JW Aramideh M Speelman HD De Haan RJ Treatment of cervical dystonia: a comparison of measures for outcome assessment Mov Disord 1998 13 4 706 712 10.1002/mds.870130417 9686779
Moore AP Blumhardt LD A double blind trial of botulinum toxin “A” in torticollis, with one year follow up J Neurol Neurosurg Psychiatry 1991 54 9 813 816 10.1136/jnnp.54.9.813 1955900
Müller J Wissel J Kemmler G Voller B Bodner T Schneider A Wenning GK Poewe W Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument J Neurol Neurosurg Psychiatry 2004 75 5 749 753 10.1136/jnnp.2003.013441 15090572
O’Brien C Brashear A Cullis P Truong D Molho E Jenkins S Wojcieszek J O’Neil T Factor S Seeberger L Cervical dystonia severity scale reliability study Mov Disord 2001 16 6 1086 1090 10.1002/mds.1226 11748739
Odergren T Tollbäck A Borg J Efficacy of botulinum toxin for cervical dystonia. A comparison of methods for evaluation Scand J Rehabil Med 1994 26 4 191 195 7878393
Pappert EJ Germanson T Myobloc/Neurobloc European Cervical Dystonia Study Group Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: randomized, double-blind, noninferiority trial Mov Disord 2008 23 4 510 517 10.1002/mds.21724 18098274
Poewe W Deuschl G Nebe A Feifel E Wissel J Benecke R Kessler KR Ceballos-Baumann AO Ohly A Oertel W Künig G German Dystonia Study Group What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport J Neurol Neurosurg Psychiatry 1998 64 1 13 17 10.1136/jnnp.64.1.13 9436721
Reichel G Cervical dystonia: a new phenomenological classification for botulinum toxin therapy Basal Ganglia 2011 1 5 12 10.1016/j.baga.2011.01.001
Scientific Advisory Group of the Medical Outcomes Trust Assessing health status and quality-of-life instruments: attributes and review criteria Qual Life Res 2002 11 3 193 205 10.1023/A:1015291021312 12074258
Simpson DM Blitzer A Brashear A Comella C Dubinsky R Hallet M Jankovic J Karp B Ludlow CL Miyasaki JM Naumann M So Y Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology 2008 70 1699 1706 10.1212/01.wnl.0000311389.26145.95 18458230
Slawek J Friedman A Potulska A Krystkowiak P Gervais C Banach M Ochudlo S Budrewicz S Reclawowicz D Rynkowski M Opala G Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections Funct Neurol 2007 22 2 95 100 17637212
Sommer S Viga R Petersen H Koletzki E Jost W Zerviton: a new tool to measure head position in patients with cervical dystonia: preliminary results Mov Disord 2009 24 Suppl 1 117 118
Stell R Thompson PD Marsden CD Botulinum toxin in spasmodic torticollis J Neurol Neurosurg Psychiatry 1988 51 7 920 923 10.1136/jnnp.51.7.920 3204400
Tarsy D Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin Mov Disord 1997 12 1 100 102 10.1002/mds.870120117 8990061
Truong DD Jost WH Botulinum toxin: clinical use Parkinsonism Relat Disord 2006 12 6 331 355 10.1016/j.parkreldis.2006.06.002 16870487
Truong D Duane DD Jankovic J Singer C Seeberger LC Comella CL Lew MF Rodnitzky RL Danisi FO Sutton JP Charles PD Hauser RA Sheean GL Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study Mov Disord 2005 20 7 783 791 10.1002/mds.20403 15736159
Tsui JK Eisen A Mak E Carruthers J Scott A Calne DB A pilot study on the use of botulinum toxin in spasmodic torticollis Can J Neurol Sci 1985 12 4 314 316 4084867
Tsui JK Eisen A Stoessl AJ Calne S Calne DB Double-blind study of botulinum toxin in spasmodic torticollis Lancet 1986 2 8501 245 247 10.1016/S0140-6736(86)92070-2 2874278
Tsui JK Fross RD Calne S Calne DB Local treatment of spasmodic torticollis with botulinum toxin Can J Neurol Sci 1987 14 3 Suppl 533 555 3676924
Weiner WJ Lang AE Movement disorders: a comprehensive survey 1989 Mount Kisco, NY Futura
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
저자가 APC(Article Processing Charge)를 지불한 논문에 한하여 자유로운 이용이 가능한, hybrid 저널에 출판된 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.